Premium
Concurrent chemotherapy with intensity‐modulated radiation therapy for locally advanced squamous cell carcinoma of the larynx and oropharynx: A retrospective single‐institution analysis
Author(s) -
Saba Nabil F.,
Edelman Scott,
Tighiouart Mourad,
Gaultney Jennifer,
Davis Lawrence W.,
Khuri Fadlo R.,
Chen Amy,
Grist William,
Shin Dong M.
Publication year - 2009
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.21120
Subject(s) - medicine , larynx , carboplatin , radiation therapy , chemotherapy , retrospective cohort study , oncology , paclitaxel , cisplatin , head and neck squamous cell carcinoma , head and neck cancer , radiology , surgery
Background We present outcome data from concurrent chemotherapy and intensity‐modulated radiation therapy (IMRT) for squamous cell carcinoma (SCC) of the larynx and oropharyx. Methods Eighty patients with laryngeal ( n = 15) or oropharyngeal ( n = 65) SCC underwent concurrent IMRT and chemotherapy (cisplatin or carboplatin/paclitaxel). Results The 3‐year overall survival (OS) and disease‐free survival (DFS) were 81.2% and 78.3%, respectively, with a median follow‐up of 31.2 months. There was a statistically significant correlation between OS and DFS with N classification ( p = .0001), but not with disease site or T classification. Toxicities compared favorably with prior reports using conventional radiation therapy. Conclusions This retrospective analysis reveals a very good outcome and an acceptable toxicity profile for patients with locally advanced SCC of the oropharynx and larynx treated with chemotherapy and IMRT concurrently. © 2009 Wiley Periodicals, Inc. Head Neck, 2009